Navigation Links
COPD Tops Asthma as the Focus Indication for Next Generation Respiratory Therapies at the 2012 American Thoracic Society Conference
Date:5/31/2012

NEW YORK, May 31, 2012 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials, updates, and intelligence recently reviewed the results presented at the American Thoracic Society (ATS) conference held May 18-23, 2012 in San Francisco, CA. The strong competition to launch the next fixed dose combination (FDC) blockbuster for chronic obstructive pulmonary disease (COPD) was of particular interest to reviewer Jennifer Stacey, Citeline's Analyst in Autoimmune/Inflammation.

(Photo: http://photos.prnewswire.com/prnh/20120531/NE16127-INFO )

In the absence of results from GlaxoSmithKline and Theravance's market-leading RELOVAIR program, top COPD trials data presented at the conference include results from Novartis' Phase III NVA237 GLOW2 trial and final Phase II data from Boehringer Ingelheim's olodaterol monotherapy program. Both drugs provided significant improvement in bronchodilation with once-daily dosing, and these studies supported the dose selections for their respective FDC trials. Mid-sized companies Almirall and Forest showed sustained success of their partnered aclidinium bromide drug program, while privately-held Pearl Therapeutics divulged eight clinical publications at ATS, revealing statistically significant efficacy results and future plans for their LAMA/LABA (glycopyrrolate+formoterol fumarate), PT003.

"The presentations at ATS this year provide further evidence of high competition to launch next generation FDC respiratory drugs. COPD has superseded asthma as the lead indication in the market race, most likely due to the FDA's new safety controls pertaining to limited use of all LABA-containing drugs in asthma as well as the unmet need for improved therapies for COPD," states Ms. Stacey, "Additionally, it appears that most companies are strategically conducting trials to launch their novel LAMA or LABA as monotherapy in advance of the registration of the associated FDC product."

Despite the notable omission of pivotal RELOVAIR trial data from this year's ATS proceedings, GSK and Theravance continue to be the trailblazers in the race to launch the next generation COPD therapy through their partnership in two key FDC programs, RELOVAIR (fluticasone furoate+vilanterol) and their LAMA/LABA combination ('719+vilanterol). With the patent expiry of Advair in 2011 and the looming expiration of Symbicort later this year, GSK has positioned itself as the front runner in capturing a large share of the future respiratory market with these two strong Phase III FDC drug programs and plans to submit regulatory RELOVAIR applications for COPD in the US and Europe in mid-2012.  However, several competitors are riding on their heels, including Boehringer Ingelheim, Novartis, Almirall/Forest, and the up-and-coming Pearl Therapeutics, with strong FDC candidates in their pipelines.

"Pearl Therapeutics is only in planning stages for their Phase III FDC program and is certainly the underdog among the current competition, but their innovative PT003 product had stellar Phase II data at ATS and they announced plans for PT010, a triple combination therapy of LAMA (glycopyrrolate), LABA (formoterol fumarate), and an inhaled corticosteroid, in one of their presentations," comments Ms. Stacey. "They will be an exciting company to watch as competitors in the FDC respiratory market race cross the finish line for novel inhaled therapies in COPD."

About Citeline
Citeline (www.citeline.com)  provides the world's most comprehensive real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator and drug intelligence. Our data is drawn from over 20,000 unique sources and analyzed by the industry's largest team – over 250 full-time expert analysts and editors.

Media Invitation
Members of the media interested in receiving a review of Citeline as well as further insight into our assessment of ATS 2012 should contact Julie McKenna at 617.415.1981 - or e-mail at Julie.mckenna@citeline.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Julie McKenna
Citeline Marketing Manager
617. 415.1981

 


'/>"/>
SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
3. Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Inverseon Announces Positive Phase IIa Asthma Study
8. Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma
9. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
Breaking Medicine News(10 mins):